|Calculated MW||This protein is fused with 6×His tag at the C-terminus, has a calculated MW of 39.3 kDa. The predicted N-terminus is Phe 19. DTT-reduced Protein migrates as 75-90 kDa due to glycosylation.|
|Other Names||TNFRSF8, CD30, D1S166E, Ki-1|
|Results||Measured by its ability to block CD30 Ligand-induced IL-6 secretion by HDLM human Hodgkin’s lymphoma cells. The ED50 for this effect is typically 0.5 - 2.5 µg/ml in the presence of 50 ng/ml of Recombinant Human CD30 Ligand.|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Human CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.
Duerkop H.,et al.Cell 68:421-427(1992).
Jung W.,et al.Mol. Immunol. 31:1329-1334(1994).
Horie R.,et al.Blood 88:2422-2432(1996).
Durkop H.,et al.Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
Gregory S.G.,et al.Nature 441:315-321(2006).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.